Authors:
Address: Department of Neurology, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences.
Journal:

Publication:

abstract

Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of latently infected JCV when hosts' immune system is impaired by HIV infection, hematologic diseases, collagen diseases, immunemodulatory therapy and so on. PML was rare but HIV infection and Natalizumab have made it much more common while the prognosis is much better than other PML. PML patients present with various signs and symptoms including hemiparesis, dementia, aphasia, visual disturbance, cranial nerve paresis, cerebellar signs and bladder bowel disturbance. Brain MRI reveals characteristic demyelinating lesions in the CNS white matter and CSF mild increase of protein with or without mild mononuclear pleocytosis. Detection of JCV genome from CSF is crucial for the clinical diagnosis of PML. PML was once thought to be fatal but some HIV infected PML patients showed halting progression or even recovery after introduction of HAART. In addition, anti-malarial drug mefloquine was found to be effective. Recovery of immunity may provoke some inflammatory responses known as immune reconstruction inflammatory syndrome (IRIS) which requires high dose corticosteroid. In Japan, we are providing free test of CSF-JCV genome and organized a unique system for surveillance and clinical research of PML. Using this system we hope to improve diagnosis and therapy of PML in Japan.

Related Articles
Review [A case of progressive multifocal leukoencephalopathy presenting white matter MRI lesions extending over the cerebral cortex and a marked decrease in cerebral blood flow on SPECT, and associated with HTLV-I infection].
Rinsho Shinkeigaku. 2005
Review [A case of progressive multifocal leukoencephalopathy presenting white matter MRI lesions extending over the cerebral cortex and a marked decrease in cerebral blood flow on SPECT, and associated with HTLV-I infection].
Takase K, Ohyagi Y, Furuya H, Nagashima K, Taniwaki T, Kira J. Rinsho Shinkeigaku. 2005 Jun; 45(6):426-30.
Review Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Lancet Neurol. 2010
Review Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Lancet Neurol. 2010 Apr; 9(4):438-46.
Review [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
Brain Nerve. 2007
Review [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
Kishida S. Brain Nerve. 2007 Feb; 59(2):125-37.
Review [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
No To Shinkei. 2007
Review [Progressive multifocal leukoencephalopathy--epidemiology, clinical pictures, diagnosis and therapy].
Kishida S. No To Shinkei. 2007 Feb; 59(2):125-37.
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Clin Infect Dis. 2005
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, Gerevini S, Bestetti A, Pedale R, Sala S, et al. Clin Infect Dis. 2005 Mar 1; 40(5):738-44. Epub 2005 Feb 1.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster